CDK4/6 Inhibitors in Breast Cancer: New Populations, Different Settings
At the American Society of Clinical Oncology (ASCO) annual meeting, a poster discussion…
Browsing Tag
CDK46
Studies Question Role of CDK4/6 Inhibitors in First-Line Advanced Breast Cancer
CHICAGO -- Upfront CDK4/6 inhibition or second-line use in advanced hormone receptor (HR)-positive/HER2-negative…
CDK4/6 Extends Reach Into Early-Stage Breast Cancer
CHICAGO -- Adding ribociclib (Kisqali) to adjuvant endocrine therapy significantly improved invasive disease-free…
CDK4/6 Inhibition Active in Recurrent Low-Grade Serous Ovarian Cancer
TAMPA, Fla. -- About a fourth of patients with recurrent low-grade serous ovarian cancer (LGSOC) obtained durable responses to…
Focus on Optimizing Use of CDK4/6 Inhibitors in Metastatic HR+ Breast Cancer
MIAMI BEACH -- Emerging data have helped optimize the use of CDK4/6 inhibitors in metastatic hormone receptor (HR)-positive…
Continuing CDK4/6 Inhibitor Beyond Progression No Help in Metastatic Breast Cancer
SAN ANTONIO -- Continuing a CDK4/6 inhibitor beyond progression did not improve survival in metastatic breast cancer but adding…
First-Line CDK4/6 Thumps Chemo in Aggressive, Advanced Breast Cancer
SAN ANTONIO -- A CDK4/6 inhibitor plus endocrine therapy combination extended progression-free survival (PFS) by nearly a year…
Clinical Challenges: Options After CDK4/6 Inhibitors in Breast Cancer
CDK4/6 inhibitors changed the treatment of hormone receptor (HR)-positive/HER2-negative metastatic breast cancer, with…
Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable Complete Clinical…
Presentation delivered at the ninth-annual Metastatic Breast Cancer Research Conference in Park City, Utah Case was reported during Phase 2 study investigating efficacy of lasofoxifene,…
Honing the Indications for Adjuvant CDK4/6 Inhibition in Breast Cancer
MIAMI BEACH -- After a bumpy start, CDK4/6 inhibitors have started to gain traction in early hormone receptor…